Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Transitional Cell 1

Interventions

Arsenic Trioxide 21Tretinoin 20Cytarabine 12Cyclophosphamide 11Busulfan 10Methotrexate 9Idarubicin 9Filgrastim 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 6Tacrolimus 5Gemtuzumab 5Etoposide 5Radiotherapy 4Clofarabine 4Antilymphocyte Serum 4Topotecan 3Mycophenolic Acid 3Mitoxantrone 3Mercaptopurine 3Daunorubicin 3venetoclax 2lintuzumab 2Whole-Body Irradiation 2Thiotepa 2Sorafenib 2Granulocyte Colony-Stimulating Factor 2Cyclosporins 2Cyclosporine 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Promyelocytic, Acute × tamibarotene × Clear all
NCT00985530 2013-10-30

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Northwestern University

Phase 1 Terminated
4 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡